SCHEMBL5170971

SCHEMBL5170971

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1cc(C)c(O)c(C)c1)CC1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
BCHE P06276 3/20 0.39
TSHR P16473 4/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP3A4 P08684 3/20 0.37
HSD17B10 Q99714 3/20 0.37
HPGD P15428 2/20 0.37
HDAC1 Q13547 1/20 0.36
CRHR1 P34998 3/20 0.35
ACHE P22303 1/20 0.35
OPRM1 P35372 2/20 0.34
OPRD1 P41143 2/20 0.34
OPRK1 P41145 2/20 0.34
CCR4 P51679 1/20 0.34
ALOX15 P16050 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766337 0.94 C5AR1 (0.38) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL4763715 0.92 C5AR1 (0.46) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5137864 0.90 C5AR1 (0.44) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL651027 0.90 C5AR1 (0.41) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL650474 0.89 C5AR1 (0.42) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5135713 0.88 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL651501 0.88 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL14099616 0.88 ALOX5 (0.34) C5AR1BCHEKDM4EALDH1A1CRHR1
SCHEMBL5134718 0.88 C5AR1 (0.43) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5134910 0.88 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed